Necrostatin-1

別名：Nec-1

製品コード：S8037 純度：99.97%

Necrostatin-1 (Nec-1) is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.

CAS No. 4311-88-0

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 29500	国内在庫あり
10mg	JPY 22000	国内在庫あり
100mg	JPY 70500	国内在庫あり
1g	JPY 220500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（256）

製品安全説明書

現在のバッチを見る：純度： 99.97%

99.97

Necrostatin-1関連製品

関連ターゲット	RIP1 kinase RIP2 kinase RIP3 kinase RIP 1 Kinase	もっと見る
関連製品	GSK'872 Necrostatin 2 racemate (Nec-1s) Mito-TEMPO RIPA-56 GSK2982772 GSK'963 GSK583 GSK2983559 (compound 3) Resibufogenin GSK'547 ICCB-19 hydrochloride HS-1371 GSK481	もっと見る
関連化合物ライブラリー	Autophagy Compound Library Apoptosis Compound Library Ferroptosis Compound Library Pyroptosis Compound Library Mitochondria-Targeted Compound Library	もっと見る

RIP kinase阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
L929	Growth Inhibition Assay	2/5 μg/ml	24 h	reverses the cell growth inhibition and cell death induced by TNFα alone as well as TNFα + zVAD	23941769
L929	Function Assay	2 μg/ml	24 h	promots caspase-6 (p20) activity and procaspase-6 cleavage	23941769
L929	Function Assay	5 μg/ml	24 h	blocks zVAD induced necroptosis and autophagy	23941769
C6	Cell Viability Assay	1 mmol/L	3 h	attenuates Shikonin induced glioma cell death	23840441
U87	Cell Viability Assay	1 mmol/L	3 h	attenuates Shikonin induced glioma cell death	23840441
C6	Cytotoxicity Assay	1 mmol/L	3 h	blocks shikonin induced necrosis	23840441
U87	Cytotoxicity Assay	1 mmol/L	3 h	blocks shikonin induced necrosis	23840441
C6	Function Assay	1 mmol/L	1.5-3 h	suppresses the expression of RIP-1 caused by shikonin	23840441
U87	Function Assay	1 mmol/L	1.5-3 h	suppresses the expression of RIP-1 caused by shikonin	23840441
TE671	Cell Viability Assay	40 μg/ml	24 h	rescues GX15-070-induced loss of cell viability	23744296
RMS13	Cell Viability Assay	40 μg/ml	24 h	rescues GX15-070-induced loss of cell viability	23744296
MEFs	Cytotoxicity Assay	2/6/20 μM	18 h	inhibits TNFα-induced cell death in RelA KO MEFs	23727581
MEFs	Function Assay	20 μM	1/2/4 h	suppresses TNFα-induced RIPK1 phosphorylation	23727581
ΔN-Karpas 299	Cytotoxicity Assay	20 μM	16 h	inhibits CD30-induced cell death	23545938
MM.1S	Cytotoxicity Assay	90 µM	1 h	blocks BAY 11-7082 induced rapid cell swelling	23527154
KMS-12-BM	Cytotoxicity Assay	90 µM	1 h	blocks BAY 11-7082 induced rapid cell swelling	23527154
HT-22	Cell Viability Assay	10 μM	12 h	protects against glutamate-induced cell death	23307752
HT-22	Function Assay	25 μM	0–30 min	inhibits ERK Activation induced by glutamate	23307752
NIH3T3	Function Assay	10/50 μM	1/3 h	ameliorates TNFα-driven complex formation	23261677
SH-EP	Apoptosis Assay	10 μM	72 h	inhibits IAP inhibitor- and Lexatumumab-induced apoptosis	22890322
HL60	Apoptosis Assay	60 μM	12 h	enhances shikonin-induced apoptosis	22837689
HL60/Adr	Apoptosis Assay	60 μM	12 h	enhances shikonin-induced apoptosis	22837689
K562	Apoptosis Assay	60 μM	12 h	enhances shikonin-induced apoptosis	22837689
K562/Adr	Apoptosis Assay	60 μM	12 h	enhances shikonin-induced apoptosis	22837689
HL60	Function Assay	60 μM	12 h	augments the caspase-3 activity	22837689
HL60/Adr	Function Assay	60 μM	12 h	augments the caspase-3 activity	22837689
K562	Function Assay	60 μM	12 h	augments the caspase-3 activity	22837689
K562/Adr	Function Assay	60 μM	12 h	augments the caspase-3 activity	22837689
HL60	Function Assay	60 μM	12 h	increases the activity of caspases, caspase 8 and 9	22837689
HL60/Adr	Function Assay	60 μM	12 h	increases the activity of caspases, caspase 8 and 9	22837689
K562	Function Assay	60 μM	12 h	increases the activity of caspases, caspase 8 and 9	22837689
K562/Adr	Function Assay	60 μM	12 h	increases the activity of caspases, caspase 8 and 9	22837689
L929sA	Apoptosis Assay	10 μM	1 h	inhibits the apoptotic response to TNF	22362767
L929sA	Apoptosis Assay	10 μM	1 h	rescues cells expressing RIPK1ΔID from TNF-induced apoptosis	22362767
L929sA	Apoptosis Assay	10 μM	1 h	abrogates the interaction of caspase-8 with FADD	22362767
TPC-1	Cell Viability Assay	100 μM	24 h	increases cellular survival	22136818
8505c	Cell Viability Assay	100 μM	24 h	increases cellular survival	22136818
SW13	Cell Viability Assay	100 μM	24 h	increases cellular survival	22136818
Jurkat	Cytotoxicity Assay	50/ 100/200 μm	1/3 h	reduces Naegleria fowleri-induced cytotoxicity	21535020
Jurkat	Function Assay	200 μm	30 min	reduces Naegleria fowleri-induced reactive oxygen species (ROS) generation	21535020
HT-22	Cytotoxicity Assay	10 μM	12 h	protects against cell death induced by 5 mmol/L glutamate	17760869
L929	Function Assay	2/5 μg/ml	24 h	reversed the autophagy induced by TNFα alone as well as TNFα + zVAD	23941769
NRK-52E	Cell Viability Assay	20 μM	24 h	inhibits increased Drp1 protein expression after TNF-α Stimulation and ATP Depletion	24351845
NRK-52E	Cell Viability Assay	20 μM	24 h	increases cell viability after TNF-α Stimulation and ATP Depletion	24351845
NRK-52E	Cell Viability Assay	20 μM	24 h	protects cells from cell death caused by ischemia injury	24351845
AGS	Cell Viability Assay	60 μm	1 h	prevents shikonin-induced cell death	24463199
L-540	Cell Viability Assay	60 μm	1 h	reduces the Givinostat/Sorafenib-induced cell death	24561519
L-540	Function Assay	60 μm	1 h	prevents the mitochondrial membrane depolarization	24561519
L-540	Function Assay	60 μm	1 h	prevents the generation of ROS	24561519
SK-Hep1	Function Assay	60 μM	18 h	blocks β-lapachone-mediated PAR accumulation and AIF translocation to the cytosol	24832602
SK-Hep1	Function Assay	60 μM	18 h	inhibits β-Lapachone-induced leakage of HMGB-1	24832602
SK-Hep1	Function Assay	60 μM	18 h	blocks β-lapachone-induced morphological change, cell death and PI uptake	24832602
Huh7	Cell Viability Assay	50 µM	24/48 h	prevents cell death of rAdHCV co-infected Huh7 cells	24973240
L929	Cell Viability Assay	30 μM	1 h	inhibits TNF-α-induced cleavage of Topo I	25095742
L929	Cell Viability Assay	30 μM	1 h	inhibits TNF-α-induced loss of cell viability	25095742
L929-A	Function Assay	50 μM	12 h	inhibits the TNFα-induced loss of mitochondrial membrane permeability	25398540
L929	Function Assay	50 μM	12 h	inhibits TNFα-induced Bid cleavage	25398540
L929-N	Function Assay	50 μM	12 h	blocks the cleavage of Caspase-3 and PARP	25398540
L929-A	Function Assay	50 μM	12 h	blocks the cleavage of Caspase-3 and PARP	25398540
L929-N	Cell Viability Assay	50 μM	24 h	blocks TNFα-induced cell death	25398540
L929-A	Cell Viability Assay	50 μM	24 h	blocks TNFα-induced cell death	25398540
KMS-12-PE	Cell Viability Assay	60 μM	5 h	inhibits SHK-induced cell death	25530098
SGC-7901	Cell Viability Assay	30 μM	1 h	suppresses oxaliplatin-mediated cell death	25767076
BxPC-3	Function Assay	20 μM	24 h	decreases the early necrotic cells	26000607
MiaPaCa-2	Function Assay	20 μM	24 h	decreases the early necrotic cells	26000607
NCI-H28	Cell Viability Assay	10 μM	24 h	prevents DAPE-induced reduction of NCI-H28 cell viability	26004138
BMDM	Function Assay	10 μM	30 min	protects cells from TAKI-induced LDH release	26381601
MEFs	Cell Viability Assay	10 μM	48 h	inhibits zVAD-promoted death of CNOT3-depleted MEFs	26437789
A549	Cell Viability Assay	50 μM	24 h	inhibits MMS-induced cell death	26472723
Jurkat T	Necroptosis assay	30 uM	24 hrs	Inhibition of necroptosis in TNF-alpha-induced human Jurkat T cells assessed as cell viability at 30 uM after 24 hrs	18467094
L929	Necroptosis assay	30 uM	24 hrs	Inhibition of necroptosis in zVAD-induced mouse L929 cells assessed as cell viability at 30 uM after 24 hrs	18467094
L929	Necroptosis assay	30 uM	24 hrs	Inhibition of necroptosis in TNF-alpha-induced mouse L929 cells assessed as cell viability at 30 uM after 24 hrs	18467094
Jurkat	Cytoprotective assay	30 uM	1 hr	Cytoprotective activity against FasL-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by FasL stimulation measured after 20 hrs by Alamar blue assay	29541357
Jurkat	Cytoprotective assay	30 uM	1 hr	Cytoprotective activity against CHX-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by CHX stimulation by Alamar blue assay	29541357
Jurkat	Cytoprotective assay	30 uM	1 hr	Cytoprotective activity against Z-VAD-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by Z-VAD stimulation by Alamar blue assay	29541357
Jurkat	Cytoprotective assay	30 uM	1 hr	Cytoprotective activity against FasL-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by FasL stimulation measured after 20 hrs by phase contrast microscopy	29541357
Jurkat	Cytoprotective assay	30 uM	1 hr	Cytoprotective activity against CHX-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by CHX stimulation by phase contrast microscopy	29541357
Jurkat	Cytoprotective assay	30 uM	1 hr	Cytoprotective activity against Z-VAD-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by Z-VAD stimulation by phase contrast microscopy	29541357
OHC	Function Assay	300 μM		increases the number of apoptotic OHCs without altering the levels of CC8 after noise exposure	24874734
OHC	Function Assay	300 μM		diminishes noise-induced AMPK activation	24874734
OHC	Function Assay	300 μM		results in a reduction of noise-induced RIP1 and RIP3 immunofluorescence	24874734
OHC	Function Assay	300 μM		decreases noise-induced swollen nuclei	24874734
OHC	Function Assay	300 μM		increases noise-induced condensed nuclei	24874734
Sf9	Function assay		30 mins	Inhibition of recombinant human GST-fused RIPK1 (1 to 497 residues) expressed in baculovirus infected insect Sf9 cells in presence of 32P-gamma-ATP after 30 mins by autoradiogram-based Western blot method, IC50 = 0.182 μM.	28280261
3T3	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necrotic cell death in mouse 3T3 cells assessed as cell viability after 24 hrs by ATP based viability assay in presence of TNFalpha and zVAD.fmk	16408008
3T3	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necrotic cell death in mouse 3T3 cells assessed as cell viability after 24 hrs by ATP based viability assay in presence of FasL and zVAD.fmk	16408008
MEF	Cell death assay		16 hrs	Inhibition of death receptor signaling mediated necrotic cell death in SV40 transformed mouse MEF cells assessed as cell viability after 16 hrs by ATP based viability assay in presence of TNFalpha, CHX and zVAD.fmk	16408008
L929	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necrotic cell death in mouse L929 cells assessed as cell viability after 24 hrs by ATP based viability assay in presence of TNFalpha	16408008
U937	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human U937 cells assessed as cell viability after 48 hrs by ATP based viability assay in presence of TNFalpha and zVAD-fmk	16408008
3T3	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in mouse 3T3 cells assessed as cell viability after 24 hrs by ATP based viability assay in presence of TNFalpha and zVAD-fmk	16408008
Jurkat	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD assessed as decreased levels of PE-conjugated LC3-II (autophagy marker) after 24 hrs by Western blot method in presence of TNFalpha	16408008
L929	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in mouse L929 cells assessed as decreased levels of PE-conjugated autophagy marker LC3-II after 24 hrs by Western blot method in presence of TNFalpha	16408008
3T3	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in mouse 3T3 cells assessed as decreased levels of PE-conjugated autophagy marker LC3-II after 24 hrs by Western blot method in presence of TNFalpha and zVAD-fmk	16408008
3T3	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in mouse 3T3 cells assessed as decreased levels of PE-conjugated autophagy marker LC3-II after 24 hrs by Western blot method in presence of FasL and zVAD-fmk	16408008
3T3	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in mouse 3T3 cells assessed as decreased levels of PE-conjugated autophagy marker LC3-II after 24 hrs by Western blot method in presence of rapamycin	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing FKBP12-based dimerization domain assessed as cell viability after 48 hrs by FACS in presence of AP1510, zVAD-fmk	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP kinase assessed as cell viability after 48 hrs by FACS in presence of AP1510, zVAD-fmk	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP K45M mutant assessed as cell viability after 48 hrs by FACS in presence of AP1510, zVAD-fmk	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP kinase domain assessed as cell viability after 48 hrs by FACS in presence of AP1510, zVAD-fmk	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing FKBP12-based dimerization domain assessed as cell viability after 48 hrs by FACS in presence of AP1510	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP kinase assessed as cell viability after 48 hrs by FACS in presence of AP1510	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP K45M mutant assessed as cell viability after 48 hrs by FACS in presence of AP1510	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP kinase domain assessed as cell viability after 48 hrs by FACS in presence of AP1510	16408008
Jurkat T	Necroptosis assay			Inhibition of TNF-alpha-induced necroptosis in FADD-deficient human Jurkat T cells, EC50 = 0.05 μM.	18467094
Jurkat	Function assay			Inhibition of endogenous RIP1 autophosphorylation in human Jurkat cells, EC50 = 0.182 μM.	18408713
Jurkat T	Necroptosis assay			Effective concentration required for inhibition of necroptosis in FADD deficient Jurkat T cells treated with TNF-alpha, EC50 = 0.49 μM.	16153840
Jurkat	Necroptosis assay			Inhibition of cellular necroptosis in TNFalpha treated FADD deficient human Jurkat cells, EC50 = 0.49 μM.	18408713
IEC18	Cell death assay			Inhibition of death receptor signaling mediated necrotic cell death in rat IEC18 cells assessed as cell viability in presence of TNFalpha and zVAD.fmk	16408008
HL60	Cell death assay			Inhibition of death receptor signaling mediated necrotic cell death in human HL60 cells assessed as cell viability in presence of TNFalpha and zVAD.fmk	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells assessed as nuclear condensation by bright field microscopy in presence of FasL, CHX and zVAD-fmk	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells assessed as organelle swelling by bright field microscopy in presence of FasL, CHX and zVAD-fmk	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells assessed as early loss of plasma membrane integrity by bright field microscopy in presence of FasL, CHX and zVAD-fmk	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells assessed as appearance of translucent cytosol in presence of FasL, CHX and zVAD-fmk	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells deficient in FADD assessed as inhibition of nuclear condensation by bright field microscopy in presence of TNFalpha	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells deficient in FADD assessed as inhibition of organelle swelling by bright field microscopy in presence of TNFalpha	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells deficient in FADD assessed as inhibition of early loss of plasma membrane integrity by bright field microscopy in presence of TNFalpha	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells deficient in FADD assessed as inhibition of appearance of translucent cytosol in presence of TNFalpha	16408008
Sf9	Function assay			Inhibition of human RIP1 K45M mutant autophosphorylation expressed in Sf9 cells	18408713
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

特性

A powerful tool for characterizing the role of necroptosis with characterized primary target.

Targets

RIP1 ^[1]
(293T cells)

490 nM(EC50)

In Vitro
In vitro	Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of Necrostatin-1. ^[1] Necrostatin-1 efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. Necrostatin-1, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM. ^[2]
Kinase Assay	RIP1 kinase assay
Kinase Assay	Phosphorylation of RIP1 requires its kinase activity. Expression constructs of FLAGtagged wild-type (WT) or a kinase-inactive pointmutant of RIP1 (K45M) are are transfected into 293T cells and RIP1 kinase assay is performed as described in the Methods in the presence of [γ-³²P]ATP for 30 min at 30℃. Samples are subjected to SDS-PAGE and RIP1 band is visualized by autoradiography. Relative intensities of radioactive bands are quantified and are shown (ratio) in this and all other autoradiographs. In parallel to kinase reactions, a sample of beads is subjected to western blot analysis using anti-RIP1 antibody to ensure equal protein amounts in kinase reactions.
細胞実験	細胞株	Jurkat, BALB/c 3T3, SV40-transformed MEF, L929
	濃度	0.01-100 μM
	反応時間	--
	実験の流れ	Cells are seeded in 96-well plates (white plates for luminescent assays; black plates for fluorescent assays; clear plates for MTT assay) at the density of 5,000-10,000 cells per well for adherent cells or 20,000-50,000 cells per well for suspension cells in 100 μl of the appropriate phenol red-free media. After incubation, we determined cell viability using one of the following methods. For the ATP assay, we used luminescence-based commercial kits and analyzed luminescence using a Wallac Victor II plate reader. For Sytox assay, we incubated cells with 1 μM Sytox Green reagent for 30 min at 37℃, and then performed fluorescent reading. Subsequently, we added 5 μl of 20% Triton X-100 solution into each well to produce maximal lysis and incubated cells for 1 h at 37℃, then performed the second reading. We calculated the ratio of values before and after Triton treatment and normalized it to the relevant controls not subjected to cytotoxic stimuli, as indicated in figure legends. For the MTT assay, we used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. For PI exclusion assays, we added 2 μg/ml PI into the medium and immediately analyzed samples using FACSCalibur. For PI-annexin V assay we used the ApoAlert Annexin V-EGFP Apoptosis Kit. For DioC6 staining, we incubated cells with 40 nM DiOC₆ for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. For ROS analysis, we incubated cells with 5 μM dihydroethidium for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. EM analyses are performed at the Harvard Medical School EM facility. We acquired bright-field images of the cells using an Axiovert 200 microscope.
実験結果図	Methods	Biomarkers	結果図	PMID
実験結果図	Immunofluorescence	RIP1 / RIP3		30462730

In Vivo
In Vivo	Necrostatin-1 (Nec-1) is a specific small molecule inhibitor of receptor-interacting protein kinase 1 (RIPK1) that specifically inhibits phosphorylation of RIPK1.
動物実験	動物モデル	Male C57BL/6 mice
	投与量	0.0468 mg/Kg
	投与経路	i.a.

参考
[1] Degterev A, et al. Nat Chem Biol, 2008, 4(5), 313-321. [2] Degterev A, et al. Nat Chem Biol, 2005, 1(2), 112-119. [3] Liang S, et al. Front Pharmacol. 2018 Nov 27;9:1378.

参考

化学情報

分子量	259.33	化学式	C₁₃H₁₃N₃OS
CAS No.	4311-88-0	SDF	Download Necrostatin-1 SDFをダウンロードする
Smiles	CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

DMSO : 57 mg/mL ( (219.79 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):